Created in 1997, Hybrigenics is a bio-pharmaceutical company with a focus on research and development of new targets & therapies against proliferative diseases.
Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist being studied in three potential indications:
- alone in chronic lymphocytic leukaemia
- in combination with imatinib in chronic myeloid leukaemia
- in prostate cancer, for use with current standards of care
Hybrigenics' research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the utility of proprietary patented DUB inhibitors against various cancer indications.
Hybrigenics Services, a Hybrigenics subsidiary, markets very specialized scientific services to researchers in all areas of life sciences who want to identify, validate and inhibit protein interactions in animal, plant or microbiological cells.